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Introduction: The purpose of this study was to assess the level of nonadherence to 
hypertension treatment and to identify the associated factors among patients with 
hypertension. 
Methods: This was a cross-sectional study. 48 participants were recruited at the urban 
polyclinic #8 in Astana city for this pilot study. The study participants were patients enrolled 
to the therapeutics appointment with diagnosis of hypertension. Overall, 48 patients 
consented to participate and filled out the self-administered questionnaires. The survey 
consisted of five sections, including questions on socio-demographic characteristics, health 
lifestyles, dietary habits, antihypertensive drug adherence, and perceptions of severity and 
susceptibility to hypertension, perception of barriers and benefits of hypertension treatment. 
Descriptive, bivariate and multivariate logistic regression analyses were conducted in Stata 
12. 
Results: The prevalence of poor adherence among study population was 43.75%. Less 
duration of hypertension (p=0.088) and shorter length of treatment (0.005) were associated 
with poor adherence, as well as the higher quantity of antihypertensive medications (p=0.011) 
and higher frequency of its intake (p=0.046). According to the HBM, low perception of 
severity of the disease (0.043), low self-efficacy to comply with antihypertensive treatment 
(0.105) and high perceived barriers (p=0.006) were also associated with poor adherence to 
antihypertension treatment. 
Conclusion: The findings of this pilot study need to be further explored in a study with a 
bigger sample size. The factors identified according to HBM model can serve as a baseline 
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The burden of noncommunicable diseases (NCD) raises large concern and become 
major public health challenge. The hypertension is a major cause of cardiovascular diseases 
(CVD) morbidity and mortality rate. Hence, the adherence to antihypertensive 
pharmacotherapies is a basis of preventing the risks of hypertension and improving 
population’s quality of life. 
Nowadays the NCD is the issue of not only developed and rich countries, but it has 
global pattern and causes growing threat for public health. Hypertension is one of the most 
significant treatable causes of morbidity and mortality. Currently, the number of deaths due 
to the consequences of high blood pressure was estimated to be 7.5 million worldwide 
(Global Health Observatory, 2008). According to statistical collection of the Ministry of 
Health (2013) of the Republic of Kazakhstan, the hypertension rate among Kazakhstani 
people was estimated to be 13391.6 per 100 000 people. In addition, the mortality rate related 
to the elevated blood pressure ranks on the first place among all deaths (Shinbolatova, 2014). 
The course of the disease can pass without symptoms during some periods of time, and 
individuals with high blood pressure may fail to seek the treatment or follow the medical 
prescriptions, thus leading to the greater risk of complications such as stroke, cardiovascular 
and renal diseases (Dusing, 2006). This makes adherence to antihypertensive therapy crucial 
to achieve controlled blood pressure among the population. 
Poor adherence to antihypertensive drug therapy is a widespread issue worldwide, 
accounting for  36.6% to 63.5% (Abegaz, 2017), with particularly high levels of poor 
adherence presented in Asian (43.5%) and African countries (63.5%). Very few studies of 
poor adherence were conducted in Kazakhstan, mainly concentrating on factors such as the 
presence of heart diseases and comorbidities (Mussina, 2017), while behavioral factors 
influencing to the poor management of antihypertensive therapy were not fully investigated. 
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Recent study in East Kazakhstan show complete non-compliance of 26.9% and partial 
compliance of 32% to the antihypertensive drug, resulting overall in 58.9% of population 
failing to manage the prescribed regimen of drug intake. This study investigated the 
sociodemographic status and clinical characteristics of the patients such as the presence of 
comorbidities and complications from heart and circulatory system diseases. However, no 
barriers to the antihypertension treatment adherence were investigated, while according to 
worldwide experience the barriers largely reflect patient’s level of knowledge, control and 
attitude to medications, making these factors critical for reducing poor adherence.  
Barriers to the optimal management of the prescribed medications mostly include 
dosing frequency, the number of the prescribed medications, lifestyle factors and satisfaction 
with medications (Osterberg, 2005). Other studies emphasized the importance of the patient’s 
perceptions about the severity, susceptibility, benefits and barriers of hypertension and its 
treatment, and evaluated their behaviors related to antihypertensive therapy based on the 
Health Belief Model (HBM) (Venkatachalam, 2015).  
Poor adherence to hypertension pharmacotherapy is a major cause of mortality due to 
increased risk of complications. Solely in Kazakhstan, mortality rate related to high blood 
pressure has a leading position among deaths from other causes and it also ranks on the 
second place in premature mortality caused by the hypertension within European countries 
(Shinbolatova, 2014). Numerous researches have demonstrated the significance of 
antihypertensive therapy on the reduction of mortality and morbidity. However, the 
determinants of poor adherence to antihypertensive medications have been deeply 
investigated mostly in western countries (Friedman, 2010 & Esposti, 2011), while in Asian 
countries there is a lack of such studies.  
Study of patients’ health beliefs is crucial for systematic assessment of its influence 
on hypertension management. The Health Belief Model (HBM) is aimed to explain the 
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significance of behavioral constructs related to certain health problems and their interactions 
with each other, which can be useful in designing effective health behavior interventions. 
This theoretical framework states that in order to drive behavior people should have intention 
generated from motivation, while motivation is a result of expectation and magnitude in our 
case to the treatment consequences. In general, HBM construct include six components 
including: (1) perceived susceptibility, (2) perceived severity, (3) perceived benefits, (4) 
perceived barriers, (5) cues to action, and (6) self-efficacy. Few studies have investigated the 
behavioral determinants of poor adherence with antihypertensive treatment. According to 
Iranian study, patients with low perceived susceptibility, severity, benefit had poor adherence 
to antihypertensive treatment (Kamran, 2014). In Chinese population, perceived 
susceptibility, barriers, cue to action and self-efficacy were associated with hypertension 
management (Zhao et all, 2015). 
In terms of Kazakhstan, there are almost no investigations about nonadherence with 
validated measures of its prevalence, and no studies on the behavioral patterns that influence 
the nonadherence.  Therefore, the aims of our study were: (1) to identify the prevalence of 
nonadherence to hypertension treatment among patients with hypertension in Astana city; and 
(2) to examine the association of nonadherence to hypertension treatment with patient’s 
socio-demographic characteristics, self-perceived health status, health lifestyle factors, and 
perceived susceptibility, severity, benefits and barriers of hypertension and its treatment 
using the Health Belief Model (HBM).  
Thus, this study’s finding will provide physicians and health care organizations with 
valuable information that possibly will generate useful measures to improve clinical 







This pilot study had cross sectional study design and was conducted in the City 
Policlinic №8 in Astana. The study participants were patients enrolled to the therapeutics 
appointment with diagnosis of hypertension. Overall, 48 patients consented to participate and 
filled out the survey questionnaires. The Questionnaire consisted of five sections, including 
questions on  socio-demographic characteristics, health lifestyle and dietary habits, Hill Bone 
compliance test (Culig, 2014), a scale measuring adherence to antihypertension treatment, 
and questions based on HBM (Onouriza, 2015). The Table 1 illustrates the eligibility criteria 
for this study. 
Table 1. Inclusion and exclusion criteria  
Inclusion criteria: 
- patients diagnosed with hypertension for at least one year 
- the prescription of drug therapy 
-  availability of informed consent of the patient to participate in the study 
 
Exclusion criteria: 
- age younger than 25 years and over 80 years; 
- the presence of acute conditions such as myocardial infarction (MI), stroke, 
acute renal failure (ARF) 
- the presence of a mental pathology that prevents a complete examination; 
  
Study variables 
The outcome variable in this study was the measure of drug adherence as assessed by 
Hill-Bone compliance scale. Hill-Bone compliance test a validated scale that specifically 
focuses on hypertensive patients. A Korean study showed a good internal consistency of this 
scale with Cronbach’s alpha =0.80 (Song et all, 2011). The original version of the scale 
contains 14 questions which are divided to the three domains; and 1) medication taking; 2) 
appointment keeping; and 3) reduced sodium intake. For our study purposes, we have 
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modified this scale by removing the domain on reduced sodium intake, because the questions 
from this section were included in the other section of our questionnaire, aimed to assess the 
dietary habits of participants in more detail. In addition, we omitted 1 more question from the 
scale on appointment keeping, because it is not relevant to our local primary healthcare 
system and patients faced difficulties with understanding this question during the pre-test of 
the questionnaire. Thus, our translated and adopted version of the Hill-Bone scale in Russian 
and Kazakh languages was comprised of 10 questions, with four-point Likert type response 
scale, such as “None of the time = 1”, “Some of the time = 2”, “Most of the time = 3” and 
“All the time = 4”.  The cut-off score of the Hill-Bone compliance scale was 16, based on the 
estimated mean among study participants. Hence, people who scored more than 16 were 
considered to have poor adherence to antihypertensive drugs, while participants who scored 
less than or equal to 16, had good adherence to hypertension treatment. 
The independent variables for this study included age, gender, marital status, 
ethnicity, education level, the occupation status, the average monthly income, the perceived 
health status, smoking status, the time starting the antihypertensive drug intake, the presence 
of comorbidities, the number of medicines prescribed and the frequency of drug intake, 
dietary habits, and HBM constructs.  
Dietary habits were measured by the scale including 9 questions, cut-off score was 6.  
Hence, participants who scored more or equal to 6, were considered to have healthy dietary 
habits. 
The five HBM constructs included perceived susceptibility (2 questions) and severity 
(2 questions) of hypertension, perceived benefits (2 questions), barriers (4 questions) and 
self-efficacy (3 questions) related to hypertension treatment and management. A Likert-type 
response scale for these questions ranged from “Totally agree” to “Totally disagree”. These 
scales were dichotomized for the analysis, by combining “Totally agree” and “Agree” in one 
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category (“agree=1), and “Disagree” and “Totally disagree” – in another (“disagree=0). For 
all HBM components, except to self-efficacy and perceived barriers, the score of “2” was 
coded as “high perception”, while scores “1” or “0” were coded as “low perception” (with 
one reversed scored item for perceived susceptibility). For the perceived self-efficacy a score 
of “3” was coded as “high self-efficacy” and scores less than 3 were coded as “low self-
efficacy”. For perceived barriers, a score more than or equal to 3 was coded as “high 
perceived barriers”, and score less than 3 was coded as “low perceived barriers”.  
 
Ethical considerations 
The study was approved by the Nazarbayev University School of Medicine Research 
Ethics Committee (NUSOM REC). Potential participants were recruited among patients 
enrolled to the therapeutics appointment. Interviewer approached consecutive participants in 
a queue to doctor appointment, described the study purpose and procedures, and took the oral 
consent. The oral consent was chosen because it mostly favors the interests of participants by 




The Stata version 12.0 was used for statistical analysis. Descriptive analysis was 
performed, with percentages for categorical variables and means with standard deviations 
(SD) for continuous variables. Chi-squared test was used bivariate analysis of the 
associations between independent variables and poor adherence to antihypertensive drug. 
Logistic regression was performed for multivariate analysis. The statistical significance level 






 The mean age of subjects was 61 years with the range from 39 to 80 years. More than 
a half of the sample were female, and the majority were of Kazakh ethnicity (Table 2).  
Table 2. Socio-demographic characteristics of the study subjects (n=48) 
Demographics n (%) 
Age 
Mean age (SD) 
     >55 years old 
     56-70 years old 
     >70 years old 
 
61 (9.66) 
11 (22.92)   
28 (58.33) 
 9 (18.75)  
Gender 
     Male 





     Married 





     Kazakh 





     High school 
     College 
     Bachelor degree 
     Post graduate 
 





     >100 000 tg 






The mean score of Hill bone compliance test was 16.44, ranging from 10 to 40.  
43.75% of patients obtained scores higher than 16 and were classified as “poorly adherent” 
patients. The total number of patients with good adherence was 27 (56.25%).  
According to the Table 3, some patient characteristics were significantly different in 
these two groups of patients with good and poor adherence. Patients with poor adherence to 
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hypertension treatment were more likely to have less duration of hypertension (p=0.088) and 
treatment (p=0.005); to have 2 or more drugs per day (p=0.011), and more frequent intake of 
medications per day (p=0.046); to have less healthy dietary habits (p=0.001), and low 
perceived severity (p=0.043), high perceived barriers (-=0.006), and low self-efficacy in 
regard to ability to comply with antihypertension medications, regular doctor appointments 
and recommendations on salt reduction, compared to patients with good adherence (p=0.105). 
Table 3. Patients’ characteristics by adherence to antihypertension medication 
Variables Good adherence (n=27) 
n (%) 
Poor adherence (n=21)  
n (%) 
p - value 
Sex 
     Male 









     Poor 
     Satisfactory 












     1-5  
     6-10 













Other chronic diseases 
     No 





18 (85.71)  
3 (14.29) 
0.959 
The length of treatment  
     ≤5 years 
     6-15 years 










Quantity of medications  
     1 
     2 










Frequency of medications  
Once a day 
Twice a day 













    Low 
    High 
 
18 (66.67) 
 9 (33.33) 
 




    Yes 









     Kazakh 
     Other 
 
20 (74.07) 






     High school 
     Bachelor degree      
 
15 (44.44)  
12 (55.56)  
 
7 (33.33) 
 14 (66.67) 
0.125 
Age  
     >55 
     55-70 










Diet Score  
 High  
 Low    
 
4 (14.81)  
23 (85.19)  
 




      No 









     Married 









     High 
     Low      
 
12 (44.44)  
15 (55.56) 
 
5 (23.81)  
16 (76.19) 
0.289 
Perceived Severity   
     High  
     Low 
 
27 (100)  
0 
 
18 (85.71)  
3 (14.29) 
0.043* 
Perceived Benefits  
     High 
     Low 
 
8 (29.63)  
19 (70.37) 
 




     High 
     Low 
 
2 (7.40)  
25 (92.6) 
 




     High  
     Low 
 
23 (85.18) 
 4 (14.82) 
 







Table 4. Results of the multivariate analysis  
 
Discussion 
The purpose of this study was to determine the level of nonadherence to hypertension 
treatment in patients attending the city polyclinic, and to find out the factors associated with 
poor adherence using self-administered questionnaire. Less than half of the sample was 
nonadherent to antihypertensive treatment in our study (43.75%), which is consistent with the 
range that was indicated for Asian countries (Abegaz, 2017), but is higher, compared to the 
prevalence of complete non-adherence as reported by the study that has been conducted in 
East Kazakhstan (26.9%) (Mussina and Tuleutayeva, 2017). The difference in the non-
adherence level with Kazakhstani study could be explained by the differences in methods 
used for assessing the adherence rates. In our study we used the scale that has been validated 
in several countries such as Korea, Persia, Malaya and etc., while the study by Mussina and 
Tuleutayeva (2017) was based on self-reported single-item questions, not tested for validity 
Variables Adjusted OR CI 95% P-value 
Perceived Barriers 
     High 












     High 










Duration of Hypertension 
     < 5 years 
     5-15 years 













Medications Quantity  
     1 
     2 















and reliability properties. On the other hand, there could be other factors influencing to the 
differences observed in adherence level, such as differences in the population characteristics, 
quality of medical services, population awareness and perceptions about hypertension and its 
treatment, health behaviors and social support (Lee, 2013).  
A plenty of studies were carried out to determine the factors associated with poor 
adherence to antihypertensive medications and treatment. Majority of the studies have 
reported that the age, sex, the presence of comorbidities with hypertension, the number of 
antihypertensive drugs and socioeconomic status were mostly associated with 
antihypertensive mediations adherence (Abegaz, 2017; Lee, 2013). Similar results were 
reported by the East Kazakhstani study where the age, sex and comorbidities or disability 
were associated with poor adherence to hypertension treatment (Mussina, 2017). In our study, 
we did not find statistically significant association of the poor adherence with any of the 
socio-demographic factors. However, the association between sociodemographic factors and 
poor adherence is complex, and may differ due to the population type and cultural variations. 
Moreover, given the small sample size of our pilot study these results need to be further 
explored and refined.  
However, other factors in our study, including the disease duration, the length of 
antihypertensive treatment, the quantity of medications prescribed, and the frequency of the 
medications’ intake were compatible with findings from previous studies conducted in the 
Asian and Western countries (Lee, 2013).  
In addition, interesting results were found in our study regarding dietary habits of the 
participants that illustrated strong association with poor adherence to antihypertensive 
treatment. Particularly, the more healthy dietary habits were reported to be practiced by 
patient, the higher was his adherence to antihypertensive treatment as well. However, the 
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association of poor adherence to antihypertensive treatment with dietary habits was not 
extensively investigated by previous researches, mostly focusing on the salt intake only.  
Health behavior plays crucial role in evaluating the reasons of poor adherence to 
antihypertensive agents. Results of this study demonstrated that most of HBM components 
had significant associations with poor adherence to antihypertension treatment. Particular, the 
strongest predictor of poor adherence were high perceived barriers towards the treatment, 
making the results consistent with the majority of previous studies in this field (Kamran, 
2014). Other two constructs that showed relationship with poor adherence were low 
perceived severity of the disease and low self-efficacy to comply with hypertension 
treatment. In contrast to perceived barriers, the association of poor adherence with perceived 
severity of the hypertension had a borderline significance in our study and has rarely been 
reported by previous studies (Joho, 2012). The perceived high self-efficacy, in other words, 
positive beliefs regarding the future possibilities in treatment, was found to contribute for the 
good adherence.  
Strengths and limitations 
This is a first study that measures adherence level to hypertension treatment using a 
validated scale on medications adherence among Kazakhstani patients. In addition, the 
assessment of adherence to hypertension treatment using Health Belief Model constructs 
have not been previously investigated in studies from Kazakhstan and most Asian countries. 
Finally, the dietary habits other than reduction of salt intake recommended to hypertension 
patients were not explored in other studies from Asian countries, thus making it unique for 
our study. The findings of this study can be used for the improvement of existing policies by 
focusing on identified issues. The effective strategies may possibly include the development 
of educational programs based on HBM model findings.  
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The study had several limitations as well. First of all, the small sample size of this 
pilot study could influence the power of the study to detect statistically significant results, 
and in further studies it is recommended to increase it to valuable numbers. Second, the 
research was carried out in only one polyclinic, making the results not completely 
generalizable for all other polyclinics in the city. The geographical area of study probably 
should be extended including both urban and rural regions. Thirds, because of the self-report 
survey the participants could have recall bias during the completion of questionnaire.  
 
Conclusion 
In conclusion, some factors associated with adherence to hypertension treatment using 
the Hill-Bone compliance test were unique for Kazakhstan and other Asian countries. In 
addition, since there are few studies on the determinants of poor adherence among 
Kazakhstani population, it is important to investigate Hill-Bone compliance test as a tool of 
adherence measurement for the applicability and psychometric properties within country. By 
considering the factors associated with antihypertensive drug adherence the further evaluation 
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1. How do you assess your health status? 
□ excellent 
□ good 
□ not good and not bad 
□ poor 
□ very poor 
 
2. When you were diagnosed with hypertension? 
□ less than 1 year 
□ 1-5 years ago 
□ 6-10 years ago  
□ 11-15 years ago 
□ more than 16 years 
 
3. Do you have any other comorbidity (chronic diseases other than hypertension)? 
□ Yes 
□ No 




4. How long have you been receiving antihypertensive medications? 
□ less than 1 year 
□ 1-5 years ago 
□ 6-10 years ago  
□ 11-15 years ago 
□ more than 16 years 
 
5. How many antihypertensive medications do you take? 
□ 1 
□ 2 
□ 3 and more 
 
6. How often do you take antihypertensive medications? 
□ Once a day 
□ Twice a day 
□ Three times or more 
 
 
Instructions: For each of the following questions regarding your medication, please 
choose one response on a scale from "None of the time" to "All the time". 
 
7-1. How often do you forget to take your high blood pressure (HBP) medicine? 
□ None of the time □ Some of the time □ Most of the time □ All the time 
 
7-2. How often do you decide not to take your HBP medicine?  
□ None of the time □ Some of the time □ Most of the time □ All the time 
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7-3. How often do you miss scheduled appointments?  
□ None of the time □ Some of the time □ Most of the time □ All the time 
 
7-4. How often do you leave the dispensary without obtaining your prescribed 
pills? (due to long line, closure of the clinic, forgot)  
□ None of the time □ Some of the time □ Most of the time □ All the time 
 
7-5. How often do you run out of HBP pills?  
□ None of the time □ Some of the time □ Most of the time □ All the time 
 
7-6. How often do you skip your HBP medicine 1–3 days before you go to the 
clinic?  
□ None of the time □ Some of the time □ Most of the time □ All the time 
 
7-7. How often do you miss taking your HBP pills when you feel better? 
□ None of the time □ Some of the time □ Most of the time □ All the time 
 
7-8. How often do you miss taking your HBP pills when you feel sick?  
□ None of the time □ Some of the time □ Most of the time □ All the time 
□  
7-9. How often do you take someone else’s HBP pills?  
□ None of the time □ Some of the time □ Most of the time □ All the time 
 
7-10. How often do you miss taking your HBP pills when you care less?  




Instructions: Indicate your agreement or disagreement with each of the following statements 
regarding your opinion about hypertension, on a scale from "Totally Agree" to "Totally 
Disagree." 
 
8-1. At my age I have no risk that I can get sick due to hypertension.  
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-2. I probably can get very sick due to hypertension. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-3. I know that hypertension can lead to the stroke. 




8-4. I know that hypertension can lead to the ischemic heart disease and other serious 
complications. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-5. When I take my antihypertensive medications regularly, I feel good, don’t have 
headaches; I don’t feel thirsty or heavy headedness. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-6. When I have high blood pressure, I wonder that something bad will happen to me 
at a time when I’ll be alone. However, when I take antihypertensive drugs, I feel better. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-7. I should take drugs till the end of life, making myself worried all the time. It is 
difficult for me to follow treatment regimen. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-8. When I feel better, I think there is no need to continue medication intake. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-9. Sometimes there is not enough money to purchase antihypertensive medications, so 
I cannot take medications regularly. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-10. I think that antihypertensive medications have a number of side effects that 
outweigh their benefits in treating hypertension. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-11. I am confident that I can take antihypertensive medications all the time following 
the prescribed regimen. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-12. I'm sure I can follow a diet low in salt, fat and cholesterol all the time. 
□ Totally agree □ Agree □ Disagree □ Totally disagree 
 
8-13. I’m sure that I can visit physician regularly to monitor my blood pressure all the 
time. 









9. What dietary habits do you follow? 
 
# Indicate/mark your agreement or disagreement with each of the 
following statements (yes = 1, no = 2) 
Yes No 
1 I think that I use low fat meal 1 2 
2 I try to eat more fruits and vegetables 1 2 
3 I prefer to add less salt in my food  1 2 
4 A high-fiber diet is being a main part of my diet continuously 1 2 
5 I try regularly to decrease animal fats from my meal 1 2 
6 I try regularly to eat Omega-3 fatty acids such as fish oil weekly 1 2 
7  I like to replace whole milk with low-fat milk to reduce total fat 
intake. 
1 2 
8 I think that I keep a healthy diet 1 2 
9 I think that healthy diet alone is not effective to control hypertension 1 2 
 
10. Do you smoke? 
□ Yes, I smoke 
□ No, I have quit smoking (move to the 13th question) 
□ No, I have never smoke (move to the 13th question) 
 
11. How many cigarettes per day do you smoke? 
□ Less than 10 cigarettes 
□ 11-20 cigarettes 
□ More than 20 cigarettes 
 
12. How long have you been smoking (years) (please write it up) ___________ 
 
13. What is your education level?  
□ High-school 
□ College 
□ High level 
□ Post-graduate  
 
14. What is your employment status? 
□ Full-time work 
□ Part-time work 








15. What is your average personal income per month? 
□ Less than or equal to 50 000 tenge 
□ 50 001 - 100000 
□ 100 001 - 150,000 
□ 150 001 – 200 000 
□ more than 200 000 tenge 
 
16. Your marital status?   
□ single 
□ married 
□ divorced or separated 
□ widowed 
 





□ Other  __________ 
 




19. How old are you? 




























   





□ очень плохое 
 
2. Когда Вам поставили диагноз гипертонической болезни? 
□ Менее 1 года назад 
□ 1-5 лет назад 
□ 6-10 лет назад 
□ 11-15 лет назад 
□ 16 лет назад или раньше 
 
3. У Вас есть сопутствующие заболевания (любые другие хронические 
заболевания, кроме гипертонии)? 
□ Да 
□ Нет 




4. Когда долго Вы уже принимаете лекарства от гипертонии? 
□ Меньше 1 года  
□ В течение 1-5 лет 
□ В течение 6-10 лет  
□ В течение 11-15 лет  
□ В течение 16 или более лет 
 
5. Сколько лекарств от гипертонии Вы принимаете?  
□ 1  
□ 2  
□ 3 или больше 
 
6. Как часто Вы принимаете свои противогипертензионные лекарства?  
□ 1 раз в день  
□ 2 раза в день 
□ 3 раза в день или чаще 
 
 
Инструкции: На каждый из нижеследующих вопросов, касающихся Вашего приема 
лекарств, пожалуйста, выберите один ответ по шкале от «Никогда» до «Всегда».  
 
7-1. Как часто вы забываете принимать свои противогипертензионные  
       лекарства? 




7-2. Как часто вы принимаете решение НЕ пить свои лекарства? 
□ Никогда Редко Часто Всегда 
 
7-3. Как часто вы пропускаете назначенный прием? 
□ Никогда Редко Часто Всегда 
 
7-4. Как часто вы не приобретаете рецепт на лекарство? (возможно из-за 
       долгих очередей, или просто забываете) 
□ Никогда Редко Часто Всегда 
 
7-5. Как часто у вас заканчиваются таблетки от гипертонии? 
□ Никогда Редко Часто Всегда 
 
7-6. Как часто вы перестаете принимать лекарства за несколько дней до 
       прихода в поликлинику? 
□ Никогда Редко Часто Всегда 
 
7-7. Как часто вы пропускаете прием лекарств из-за хорошего  
       самочувствия? 
□ Никогда Редко Часто Всегда 
 
7-8. Как часто вы пропускаете прием лекарств из-за плохого  
       самочувствия? 
□ Никогда Редко Часто Всегда 
 
7-9. Как часто вы принимаете чужие противогипертензионные  
         лекарства? 
□ Никогда Редко Часто Всегда 
 
7-10. Как часто вы пропускаете прием лекарств по небрежности? 




Инструкции: Отметьте Ваше согласие или несогласие с каждым из нижеследующих 
утверждений, касающихся Вашего мнения о гипертонии, по шкале от «Полностью 
согласен» до «Совершенно не согласен». 
 
8-1. В моем возрасте, я возможно не рискую сильно заболеть вследствие 
гипертонии. 
□ Полностью  
согласен 
Согласен Не согласен Совершенно  




8-2. Возможно, что я могу сильно заболеть вследствие гипертонии. 
□ Полностью  
согласен 
Согласен Не согласен Совершенно  
     не согласен 
 
8-3. Я знаю, что гипертония может привести к инсульту.  
□ Полностью  
согласен 
Согласен Не согласен Совершенно  
     не согласен 
 
8-4. Я знаю, что гипертония может привести к ишемической болезни  
       сердца или другим серьезным осложнениям.  
□ Полностью 
согласен 
Согласен Не согласен Совершенно  
     не согласен 
 
8-5. Когда я регулярно принимаю лекарства, я чувствую себя хорошо, без 
       головных болей; я не чувствую жажды или тяжести в голове.   
□ Полностью  
согласен 
Согласен Не согласен Совершенно 
     не согласен 
 
8-6. Когда у меня высокое давление, я беспокоюсь что со мной случится 
       что-то плохое, в то время, когда я буду один. Но когда я пью  
       лекарства, я чувствую себя спокойно.  
□ Полностью  
согласен 
Согласен Не согласен Совершенно 
     не согласен 
 
8-7. Я должен принимать лекарства от гипертонии до конца жизни, заставляя 
себя беспокоиться. Мне трудно следовать режиму лечения. 
□ Полностью  
согласен 
   
     не согласен 
 




   
     не согласен 
 
8-9. Иногда не хватает денег на покупку лекарств от гипертонии, из-за этого я НЕ 
могу регулярно принимать лекарства. 
□ Полностью 
согласен 
   
     не согласен 
 
8-10. Я думаю, что лекарства имеют ряд побочных эффектов, которые 
перевешивают их преимущества в лечении гипертонии. 
□ Полностью  
согласен 
   




8-11. Я уверен, что смогу принимать лекарства от гипертонии, следуя 
назначенному режиму все время 
□ Полностью 
согласен 
Согласен Не согласен Совершенно 
      не согласен 
 
8-12. Я уверен, что смогу придерживаться диеты с низким содержанием соли, 
жиров и холестерина все время 
□ Полностью  
согласен 
Согласен Не согласен Совершенно  
     не согласен 
 
8-13. Я уверен, что смогу регулярно посещать врача для мониторинга моего 
давления все время 
□ Полностью 
согласен 
Согласен Не согласен Совершенно 
     не согласен 
 
 
9. Какие диетические привычки Вы соблюдаете? 
 
 Отметьте Ваше согласие или несогласие с каждым из 
нижеперечисленных утверждений (да=1, нет=2) 
да нет 
9-1 Я думаю я употребляю пищу с низким содержанием жира 1 2 
9-2 Я стараюсь есть больше фруктов и овощей 1 2 
9-3 Я предпочитаю добавлять мало соли в мою пищу 1 2 
9-4 Пища с высоким содержанием клетчатки является основной частью 
моей диеты в течение продолжительного времени 
1 2 
9-5 Я регулярно стараюсь уменьшить количество животного жира в моей 
диете 
1 2 
9-6 Я стараюсь регулярно употреблять Омега-3 жиры в виде рыбьего жира 
каждую неделю. 
1 2 
9-7 Я предпочитаю заменять домашнее молоко на молоко с низким 
содержанием жира. 
1 2 
9-8 Я думаю у меня здоровое питание 1 2 




10.       Курите ли вы? 
□ да, я курю  
□ нет, я бросил(а) курить (перейдите к вопросу 13) 




11. Сколько сигарет в день Вы курите? 
□ 10 или меньше сигарет 
□ 11-20 сигарет  
□ Более 20 сигарет 
 
12. Сколько лет Вы уже курите? (впишите)_____________________ 
 
 
13. Ваше образование?  
□ Среднее 
□ Средне-специальное   
□ Высшее 
□ Последипломное  
  
14. Ваш статус занятости? 
□    Полный рабочий день 
□    Неполный рабочий день 
□    Временная работа 
□    Пенсионер 
□    Безработный  
□    Домохозяйка 
□    Другое (укажите)____________  
 
15. Ваш средний доход за месяц?   
□ меньше чем 50,000 тенге 
□ 50,000 - 99,000 
□ 100,000 - 149,000 
□ 150, 000 – 200, 000 
□  больше чем 200,000 
 
16. Семейное положение?   
□ холост/не замужем 
□ женат/замужем 
□ разведен (-а) 
□ вдовец (-а) 
 
17. Укажите Вашу национальность: 
□ Казах (-шка) 
□ Руский (-ая) 
□ Украинец (-ка) 
□ Немец (-ка) 
□ Другая (впишите)_____________ 
 




19. Ваш возраст на данный момент? 
 




/___ /___ /2018 /__ __ __ 
1. Өзіңіздің денсаулығыңызды қалай бағалайсыз? 




□ өте нашар 
2. Сізге гипертония диагнозін қашан қойды? 
□ 1 жыл бұрын 
□ 1-5 жыл арасында 
□ 6-10 жыл бұрын 
□ 11-15 жыл бұрын 
□ 16 жыл бұрын, не одан да бұрын 




□ Егер бар болса,  қандай созылмалы ауру (аңықтаңыз)________________ 
____________________________________________________________ 
4. Қанша уақыт бойы гипертонияға қарсы дәрілерді қабылдап жүрсіз? 
□ 1 жылдан кем  
□ 1-5 жал аралығанда 
□ 6-10 жал аралығанда 
□ 11-15 жал аралығанда 
□ 16 жылдан артық 
5. Гипертонияға қарсы қанша дәрілерді қабылдап жүрсіз? 
□ 1  
□ 2  
□ 3 және одан көп 
6. Гипертонияға қарсы дәрілерді қандай жиілікпен қабылдап жүрсіз? 
□ күніне 1 мезгіл 
□ күніне 2 мезгіл 
□ күніне 3 мезгіл және одан көп 
 
 
Нұсқаулық: Дәрілерді қабылдауыңызға байланысты төменде келтірілген   сұрақтарға 
жауапты “Ешқашан”-нан “Әрдайым”-ға дейінгі шкаладан таңдаңыз. 
 
7-1. Қаншалықты жиі сіз гипертонияға қарсы дәрілеріңізді қабылдауға ұмытып 
кетесіңз? 
□ Ешқашан Сирек Жиі Әрдайым 
 
7-2. Қаншалықты жиі сіз дәрілеріңізді ішпеймін деп шешім қабылдайсыз? 
□ Ешқашан Сирек Жиі Әрдайым 
 
7-3.  Қаншалықты жиі сіз дәрігер қабылдауын жіберіп тұрасыз? 




7-4.  Қаншалықты жиі сіз дәрілер рецептін алмайсыз? (мүмкін, үлкен кезектер 
үшін, не ұмытып кеткендіктен) 
□ Ешқашан Сирек Жиі Әрдайым 
 
7-5.  Қаншалықты жиі сіз дәрілеріңіздің бітіп қалған уақыттары болды? 
□ Ешқашан Сирек Жиі Әрдайым 
 
7-6  Қаншалықты жиі сіз емханаға келердің алдында дәрілеріңізді ішуді бірнеше 
күн бұрын тоқтатасыз? 
□ Ешқашан Сирек Жиі Әрдайым 
 
7-7.  Қаншалықты жиі сіз өзіңізді жақсы сезінгендіктен дәрілеріңізді ішуді 
қоясыз? 
□ Ешқашан Сирек Жиі Әрдайым 
 
7-8. Қаншалықты жиі сіз өзіңізді нашар сезінгендіктен дәрілеріңізді ішуді қоясыз?  
□ Ешқашан Сирек Жиі Әрдайым 
 
7-9. Қаншалықты жиі Сіз басқа біреудің гипертонияға қарсы дәрісін ішесіз? 
□ Ешқашан Сирек Жиі Әрдайым 
 
7-10. Қаншалықты жиі өзіңіздің немқұрайлығыңыздықтан сіз дәрілеріңізді 
қабылдамайсыз? 
□ Ешқашан Сирек Жиі Әрдайым 
 
 
Нұсқаулық: Төменде келтірілген гипертония туралы пайымдауларға өзіңіздің 
пікіріңізді “Толығымен келісемін”-нен “ Мүлдем келіспеймін” деген шкаласымен 
жауабыңызды көрсетініз. 
 
8-1. Менің жасымда гипертонияның салдарынан аурып қалу қауіпі жоқ деп 
есептеймін. 
□ Толығымен  
келісемін 
Келісемін Келіспеймін Мүлдем  
      келіспеймін 
8-2. Мен гипертонияның салдарынан ауырып қалуым мүмкін деп ойлаймын. 
□ Толығымен  
келісемін 
Келісемін Келіспеймін Мүлдем 
      келіспеймін 
8-3. Мен гипертонияның инсультқа алып келетінін білемін. 
□ Толығымен  
келісемін 
Келісемін Келіспеймін Мүлдем  




8-4 Мен гипертонияның жүректің ишемиялық ауруларына және басқа да 
асқынуларға алып келетінін білемін. 
□ Толығымен  
келісемін 
Келісемін Келіспеймін Мүлдем  
     келіспеймін 
8-5. Мен дәрілерді ұдайы ішкенде, өзімді жақсы сезінемін, шөл сезімі болмайды 
және есім анық болады. 
□ Толығымен  
 келісемін 
 
Келісемін Келіспеймін Мүлдем 
     келіспеймін 
 
8-6. Дәріліерді ішпегендіктен өзім жалғыз қалғанда бір нәрсе болып қалама деп 
қорқамын. Алайда, дәрілерді ішкен уақытта өзімді байсалды сезінемін. 
□ Толығымен  
келісемін 
Келісемін Келіспеймін Мүлдем 
     келіспеймін 
8-7. Маған гипертонияға қарсы дәрілерді өмір бойы қабылдау қажет. Осы рәсімді 
сақтау маған қиындық туғызады. 
□ Толығымен 
 келісемін 
Келісемін Келіспеймін Мүлдем 
      келіспеймін 
8-8. Жағдайым жақсарған кезде дәрілерді қабылдау қажеттілігі жоқ деп 
есептеймін. 
□ Толығымен  
келісемін 
Келісемін Келіспеймін Мүлдем  
    келіспеймін 
8-9. Кейбірде гипертонияға қарсы дәрілерді алуға ақшам жетпейді, сол себептен 
дәрілерді қабылдай алмаймын 
□ Толығымен  
келісемін 
Келісемін Келіспеймін Мүлдем  
      келіспеймін 
8-10. Гипертонияға қарсы дәрілердің жағымсыз әсерлері оның емдеу 
артықшылықтарынан асып түседі деп есептеймін 
□ Толығымен  
 келісемін 
Келісемін Келіспеймін Мүлдем 
      келіспеймін 
8-11. Мен гипертонияға қарсы дәрілерді белгіленген рәсімге сай қабылдай 
алатыныма сенімдімін 
□ Толығымен  
 келісемін 
Келісемін Келіспеймін Мүлдем  
      келіспеймін 




Келісемін Келіспеймін Мүлдем 
      келіспеймін 
   
8-13. Мен дәрігерлерді қан қысымын ұдайы мониторингтеу үшін әрдайым 
қабылдауын келіп тұратыныма сенімдімін 
□ Толығымен  
 келісемін 
Келісемін Келіспеймін Мүлдем 




9. Қандай диеталық дағдыларды ұстанасыз? 
 
# Төменде келтірілген пайымдаулармен келісетініңізді, не 
келіспейтініңізді таңдаңыз (иә=1, жоқ=2) 
иә жоқ 
9-1 Мен майлылығы аз тағамдарды қолданамын деп ойлаймын 1 2 
9-2 Мен жеміс пен көкөністерді көбірек жеуге тырысамын 1 2 
9-3 Мен тағамға тұзды аз мөлшерда салғанды қалаймын 1 2 
9-4 Жасұныққа бай тағам менің рәсімімнің негізгі бөлігі болып саналады, 
яғни мен көбінесе жарма, көкөністер мен жемістерді қолданамын 
1 2 
9-5 Әрдайым тағамның құрамында жануар майын азайтуға тырысамын 1 2 
9-6 Мен үнемі тамақта Омега -3 майларының болуын қадағалаймын, 
басқаша айтқанда балық өнімдерін апталық рәсімге косуға 
тырысамын 
1 2 
9-7 Үй сүтінен көрі майлылығы аз сүтті ішуге тырысамын 1 2 
9-8 Мен пайдалы тағам жеймін деп ойлаймын 1 2 




10. Темекі шегесіз бе? 
□ Иә, темекі шегемін 
□ Жоқ, темекі шегуді тастадым (бірден 13 сұраққа көшіңіз) 
□ Жоқ, темекі шекпеймін (бірден 13 сұраққа көшіңіз) 
 
11. Күніне қанша темекі шегесіз? 
□ 10 немесе одан кем  
□ 11-20 темекі 
□ 20 темекіден көп 
 
12. Темекі шекеніңізге қанша жыл болды?(аңықтаңыз)_____________________ 
 
13. Сіздің білім деңгейіңіз:  
□ Орта мектебі 
□ Орташа арнаулы (техникум, колледж, училище) 
□ Жоғары 
□ Дипломнан кейінгі 
 
 
14. Профессиональдік мәртебеңіз: 
□ Толық күндік жұмыс 
□ Жарты күндік жұмыс 





□ Үй шаруасындағы әйел 
□ Басқасы____________ 
 
15. Орташа айлығыңызды нұсқаңыз:   
□ 50 000 теңгеден кем 
□ 50 000 - 99 000 
□ 100 000 - 149 000 
□ 150 000 – 200 000 
□ 200 000 жоғары  
 











□ Басқа  __________ 
 
18. Жынысыңызды аңықтаңыз 
□ ер адам 
□ әйел адам 
 
19. Қазіргі уақыттағы жасыңызды жазыңыз  
 





















































Verbal Informed Consent  
 
The topic: Determinants of poor adherence to antihypertensive treatment among 
patients in Astana city 
 
This pilot study is aimed to assess the level of adherence to antihypertensive medications and 
determine possible barriers to nonadherence among patients in Astana city.  
 
The participation in study will take approximately 20 minutes. The questionnaire mostly 
comprise of questions with several options, where you can choose only one answer. It has 
five sections: questions on sociodemographic characteristics, lifestyles, antihypertensive drug 
adherence, and perceptions of severity and susceptibility to hypertension, perception of 
barriers and benefits of hypertension treatment. 
 
Your participation is voluntary and you can withdraw from the interview at any stage that 
will have no consequences on you.  
 
All information will be anonymous. You will not be asked to sign or to put your name. Every 
questionnaire will have unique number or code for further evaluation. Following the transfer 
of answers to database, the hard copies of your questionnaires will be destroyed. The 
database will be saved in the computer of PI under the password.  
 
There are no potential risks involved in this study and you always can stop participation at 
any stage of interview without any consequences. There are no direct benefits for you; 
however your participation in this study will help to develop programs on improvement of the 
adherence to antihypertension treatment in patients. 
 
The study is conducted by Botagoz Salkhayeva, Master of Public Health student at the 
School of Medicine of Nazarbayev University. 
Contact information: E-mail: bsalkhaeva@nu.edu.kz, Tel: 87758198075 
 
The project is controlled by Dr. Raushan Alibekova, raushan.alibekova@nu.edu.kz 
 
Do you agree to participate in this study knowing that you can withdraw at any point with no 
consequences to you?  
 
 
[If YES, begin the interview.] 
 





Название темы: Факторы связанные с низкой приверженностью к 
антигипертензивному лечению среди пациентов города Астаны 
 
Это пилотное исследование нацелено на изучение уровня приверженности пациентов к 
приему антигипертензивных препаратов и выявление факторов, связанных с 
несоблюдением режима приема лекарственных средств. 
 
Участие в данном опросе займет приблизительно 20 минут. Вопросник в основном 
состоит из вопросов с множественным вариантом ответов, из которых нужно будет 
выбрать один подходящий для вас ответ. Вопросник состоит из пяти разделов: вопросы 
о социально-демографических характеристиках, образе жизни и диетических 
привычках, приверженности к антигипертензивной терапии, о восприятии 
подверженности к гипертонии и ее серьезности, о выгодах и препятствиях касательно 
лечения гипертонии. 
 
Ваше участие является добровольным, и Вы имеете право прекратить участие в любой 
момент, что не повлечет за собой никаких последствий. 
Вся информация будет анонимной. Вас не попросят написать свое имя или подписать 
что-либо. Каждому вопроснику будет присвоен уникальный идентификационный 
номер для дальнейшего анализа. После того, как вопросники будут переведены в базу 
данных, письменные анкеты будут уничтожены. База данных будет хранится на 
компьютере исследователя, который защищен паролем.  
 
Потенциальных рисков от участия в данном исследовании нет. Прямой выгоды для вас 
также не существует, однако, Ваше участие в данном исследовании поможет в 
разработке программ по улучшению приверженности к антигипертензивной терапии 
среди пациентов. 
 
Ответственным за этот проект является Ботагоз Салхаева, студентка магистратуры по 
общественному здравоохранению Школы Медицины Назарбаев Университета. 
Контактные данные: E-mail” bsalkhaeva@nu.edu.kz, тел: 87758198075. 
Научный руководитель проекта: Др. Раушан Алибекова raushan.alibekova@nu.edu.kz 
 
Вы согласны участвовать в этом исследовании, будучи информированным о том, что 
вы можете выйти из исследования в любой момент без каких-либо последствий для 
вас? 
 
[Если Да, то начните опрос] 
 





Ауызша ақпараттандырылған келісім 
 
Тақырыбы: Астана қаласының тұрғындары арасында гипертонияға қарсы ем 
қабылдау бейілділігінің бөгеттері 
 
Бұл жоба жоғары қан қысымы бар науқастардың дәріге деген бейілділігін, яғни дәріні 
нұсқаулықпен жән тура уақытымен қабылдау деңгейін және де оны қабылдамауға алып 
келетін бөгеттерді зерттейді.  
 
Сауалнаманы толтыруға шамамен 20 минут кетеді. Сұрақтар көбінесе бірнеше 
жауаптармен келеді, ішінен біреуін таңдау керек. Сауалнама бес тараптан турады: 
әлеуметтік және демографиялық сұрақтар, өмір салтыңыз және диета жайлы сұрақтар, 
дәрілерге қаншалықты бейімділігіңізді, және гипертонияға бейімділік пен оның 
қауіптілігі қабылдануы туралы, сондай-ақ гипертонияны емдеудің пайдасы мен соның 
жолындағы кедергілер туралы сұрақтар. 
 
Бұл сауалнамаға қатысу ерікті болып табылады, және кез-келген уақытта сауалнамаға 
қатысуды тоқтатуға құқығыңыз бар, осы жағдайда ешқандай салдар болмайды. 
 
Барлық ақпарат анонимді турде жиналады. Сізден атыңызды жазуыңыз немесе құжатта 
қолыңыз сұралмайды. Барлық сауалнама қағаздарына жеке реттік сан беріліп, 
компьютерге еңгізіледі. Еңгізіліп біткен соң, қағаз сауалнамалары жойылады. 
Компьютерге көшкен файл зерттеушінің компьютерінде сақталады. Компьютерде 
құпия сөз тұрады.  
 
Бұл жоба ешқандай тәуекел туғызбайды. Сондай-ақ сіз үшін тікелей жеке пайда 
қарастырылмаған, алайда сіздің осы зерттеуге қатысуыңыз емделушілер арасындағы 
гипертонияға қарсы емге деген бейілділікті жақсарту бойынша бағдарламаларды 
әзірлеуге көмегін тизізеді. 
 
Жобаға жауапты тұлға: Ботагөз Салхаева, Назарбаев Университеті Медицина 
мектебінің қоғамдық денсаулық сақтау магистратурасының студенті. Байланыс 
ақпараты: E-mail: bsalkhaeva@nu.edu.kz; телефоны: 87758198075. 
Жоба жетекшісі: Др. Раушан Әлібекова, raushan.alibekova@nu.edu.kz 
 
Сіз қандай да бір салдарсыз зерттеуден кез келген уақытта шығып кете алатыныңыз 
туралы мағлұмат ала тұра осы зерттеуге қатысуға келісіміңізді бересіз бе?  
 
    [Егер ИӘ деп жауап берсе, сауалнаманы бастаңыз] 
 
    [Егер ЖОҚ деп жауап берсе, қатысушыға уақытын бөлгені үшін алғыс айтыңыз]   
 
